# Role of Roflumilast in Ulcerative Colitis

> **NCT05684484** · PHASE4 · COMPLETED · sponsor: **Tanta University** · enrollment: 52 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Roflumilast 500 MCG Oral Tablet [DALIRESP]
- **DRUG:** amino salicylic acid

## Key facts

- **NCT ID:** NCT05684484
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-01
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-09-15
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05684484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05684484, "Role of Roflumilast in Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05684484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*